...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Biotech Valuation
11
Mar 28, 2021 07:07PM
8
Mar 29, 2021 01:07PM
9
Mar 30, 2021 04:46PM

fouremm-

I'm sure you're right about the importance of analysts' coverage. With epigenetics being such a new field, investors can't assess the risks or potential. So they keep away. Of course, it's also a new field to analysts. So perhaps that's why they prefer to stay away too! 
I don't need an analyst to tell me ABL has a good future. If I had more cash I'd be buying buckets of shares at this ridiculously low price.

8
Mar 31, 2021 12:38AM
6
Mar 31, 2021 07:06AM
11
Mar 31, 2021 10:58AM
8
Mar 31, 2021 11:14AM
Share
New Message
Please login to post a reply